Background: To develop protein therapeutics from exogenous sources, it is necessary to mitigate the risks of eliciting an anti-biotherapeutic immune response. A key aspect of the ...
Andrew S. Parker, Wei Zheng, Karl E. Griswold, Chr...
The key requirement for successful immunochemical assay is the availability of antibodies with high specificity and desired affinity. Small molecules, when used as haptens, are no...
Mahender Kumar Singh, Shilpy Srivastava, G. P. S. ...
We consider the problem of revenue-optimal dynamic mechanism design in settings where agents' types evolve over time as a function of their (both public and private) experien...
We present a fully probabilistic stick-figure model that uses a nonparametric Bayesian distribution over trees for its structure prior. Sticks are represented by nodes in a tree i...
Edward Meeds, David A. Ross, Richard S. Zemel, Sam...
Given multiple possible models b1, b2, . . . bn for a protein structure, a common sub-task in in-silico Protein Structure Prediction is ranking these models according to their qua...